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Abstract
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer
patients in the UK. It discusses the evidence base pertaining to the management of metastatic neck disease in
the setting of an unknown primary and provides recommendations on the work up and management for this
group of patients receiving cancer care.
Recommendations
• All patients presenting with confirmed cervical lymph node metastatic squamous cell carcinoma and no apparent primary
site should undergo:
○ Positron emission tomography-computed tomography whole-body scan. (R)
○ Panendoscopy and directed biopsies. (R)
○ Bilateral tonsillectomy. (R)
• Tongue base mucosectomy can be offered if facilities and expertise exists. (G)
• Concomitant chemotherapy with radiation should be considered in patients with an unknown primary. (R)
• Concomitant chemotherapy with radiation should be offered to suitable patients in the post-operative setting, where indi-
cated. (R)
• Neo-adjuvant chemotherapy can be used in gross ‘unresectable’ disease. (R)
• Patients should be followed up at least two months in the first two years and three to six months in the subsequent years. (G)
• Patients should be followed up to a minimum of five years with a prolonged follow up for selected patients. (G)
• Positron emission tomography–computed tomography scan at three to four months after treatment is a useful follow-up
strategy for patients treated by chemoradiation therapy. (R)
Introduction
An unknown primary is defined as a squamous cell car-
cinoma (SCC) presenting in a lymph node or nodes in
the neck with no primary index site in the head and
neck having been identified. These patients are best
assessed comprehensively through a dedicated neck
lump clinic. As part of this assessment the lymph
node should be sampled and in general it is recognised
that this is best achieved by ultrasound-guided fine
needle aspiration (FNA) cytology and/or core biopsy
under ultrasound guidance. The receipt of a cytological
or histological report confirming SCC initiates the need
for further investigation.
Clinical presentation
Neck lumps presenting with no discernible primaries
can be solid or cystic lesions, which can be solitary
or multiple lumps. The lumps are usually located in
level 2, followed by level 3, with bilateral involvement
and other symptoms (i.e. pain and dysphagia) reported
in less than 10 per cent. The clinical N stage at presen-
tation is usually N2a, N2b and N2c.1 The presence of
cystic malignant metastases in level 2 is often consid-
ered to be a hallmark of human papilloma virus
(HPV)-related squamous carcinoma, usually with sub-
clinical primaries in the oropharynx.1 The first echelon
lymph node or nodes, which are involved in SCC can
act as an indicator for the potential origin of the
index primary are shown in Table I.
It should be also noted that patients presenting with
supraclavicular lymphadenopathy may represent a dif-
ferent clinical entity,2 due to the potential for associ-
ation with infraclavicular neoplasms, such as lung
cancer.
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Clinical examination of the nose, post-nasal space, oral
cavity, oropharynx, larynx and hypopharynx, including
palpation of the oral cavity and tongue base should be
carried out under direct vision and using rigid and flex-
ible endoscopes as appropriate. The skin and scalp of
the head and neck region should be examined to
ensure that there are no significant cutaneous lesions.
If there is an obvious lesion, or high suspicion of a
lesion, then further management in the form of
imaging and panendoscopy of that sub-site should be
carried out. If there is no obvious or highly suspicious
lesion on out-patient assessment, then the patient
should be regarded as having an unknown primary
and should be evaluated further, this clinical entity
being known as a ‘clinical’ unknown primary. To try
to determine the site of the primary the following inves-
tigations and findings should be collated.
Pathology of lymph nodes
The advantage of a core biopsy over FNA cytology is
that a clearer histological picture can be determined.3
Although this is generally used to differentiate
between squamous, thyroid, salivary, breast or bron-
chial origins, it may be possible from the cell architec-
ture to suggest the potential origin of the index primary.
Even though immuno-histochemical techniques may
not be able to suggest the tumour origin they may,
however, potentially exclude sites, e.g. by the use of
lung or thyroid markers. More specific investigations
such as identification of Epstein-Barr virus (EBV)
may correlate highly with a nasopharyngeal site.
Human papilloma virus is a significant aetiological
factor in oropharyngeal cancer and so the identification
of HPV 16 and 18 in a lymph node sample would be
strongly suggestive of an oropharyngeal origin.1,4 P16
positivity is highly predictive of HPV overexpression
and may be used as a surrogate marker to indicate the
HPV status.
Cross-sectional imaging
All patients should have computed tomography (CT)
imaging from skull base to diaphragm as part of the
assessment of a newly diagnosed SCC of the head
and neck.1 In the clinical scenario of an unknown
primary, it would be appropriate to undertake this as
it would assess and confirm the extent of the
lymphadenopathy and whether there is a second
primary or metastasis in the lung. Computed tomog-
raphy imaging may show evidence of a potential
index primary site, although in general, it is infrequent-
ly of significant value in diagnosing low-volume
tumours in the head and neck. If the disease presents
in a level 2/3 lymph node magnetic resonance
imaging (MRI) of the oropharynx, and in particular
the tongue base, tonsil and tonsil lingual angle,
should be carried out. It could be argued that all
unknown primary patients should have an MRI of the
neck up to skull base. It should be borne in mind,
however, that positron emission tomography–com-
puted tomography (PET-CT) may be carried out as
the first-line investigation of these patients in which
case ‘plain’ CT should not be carried out.
Positron emission tomography–computed tomography
fusion scan
Positron emission tomography-computed tomography
scanning is the recognised investigation of choice in
the assessment of the unknown primary and has been
shown to be superior to CT scanning alone. Recent
meta-analysis reported an identification rate of 44 per
cent, a sensitivity of 97 per cent and a specificity of
68 per cent.5,6 The evidence in support of this modality
is level 3 and is based on observational series. Within
this assessment it should be noted that there is a signifi-
cant false-positive identification rate associated with
PET–CT scan. Despite these limitations, PET–CT
has now been confirmed as not only the imaging
modality of choice in the investigation of an
unknown primary, but is now also regarded as the
current standard of care.1
Panendoscopy
Following each of the clinical and radiological assess-
ments it is necessary to carry out panendoscopy of the
upper aerodigestive tract under general anaesthesia.
The timing of this should be following the comple-
tion of all of the imaging as any instrumentation and
biopsy of these areas prior to scanning would com-
promise the accuracy of the subsequent radiological
assessments. In addition, imaging may identify a
potential primary site for a targeted biopsy.
Under general anaesthesia, each of the subsites of the
head and neck should be examined under direct vision
and by use of all types of straight and angled telescopes
appropriate to that area. The subsites which should be
examined are the nose, paranasal sinuses, nasopharynx,
oral cavity, hard and soft palates, tongue base, tonsil,
posterior pharyngeal wall, vallecula, supraglottis,
glottis, subglottis, pyriform fossa, post-cricoid region
and proximal oesophagus. Palpation of oral cavity
and tongue base should also be carried out.
In any of these areas if there is any suspicion of
ulceration, change in colour, asymmetry or fullness,
then the area should be photographed and appropriate
deep biopsies taken. If there is no obvious lesion,
TABLE I
FIRST ECHELON LYMPH NODES FOR VARIOUS
PRIMARY SITES
Level 1 Oral cavity, oropharynx
Level 2 Oral cavity, oropharynx, larynx, nose, hypopharynx,
parotid, nasopharynx
Level 3 Oral cavity, oropharynx, larynx, hypopharynx, thyroid,
nasopharynx
Level 4 Larynx, thyroid, hypopharynx, oesophagus
Level 5 Nasopharynx, hypopharynx, thyroid, oropharynx
Level 6 Thyroid, larynx, hypopharynx, cervical oesophagus
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then the question of random biopsies arises. Although
there is little evidence in support of this long-standing
practice, biopsy of the post-nasal space, tongue base
and/or pyriform fossa would still appear to be
common practice especially if the positive lymph
node is one of the first echelon lymph nodes draining
the index site being biopsied.
There is an evolving evidence base in support of ever
increasing oropharyngeal lymphoid tissue resection. It is
now accepted that bilateral tonsillectomy should be
carried out. An extension of this principle is an increas-
ing body of evidence in support of excision or sampling
the lingual tonsil (tongue base mucosectomy),7–9 which
is best accomplished by transoral robotic surgery.10,11
Although this increases the yield of squamous carcin-
oma primaries the effect that this might have on structure
and function within the oropharynx and ultimately how
it relates to survival needs clarification.
Most current groups would suggest that PET–CT
imaging, in conjunction with panendoscopy, directed
biopsy as appropriate and bilateral tonsillectomy offer
the greatest chance of identifying the occult primary
tumour in the routine clinical setting. The role of
tongue base mucosectomy by transoral laser or
robotic approach, with or without PET–CT or HPV
positivity needs prospective evaluation.
Following detailed clinical, radiological and opera-
tive assessment, if an index primary site is identified
then treatment should be according to the guidelines
for that site with nodal metastasis. If each of these
investigations is negative, then this should be regarded
as a ‘true’ unknown primary and the treatment consid-
ered as such.
Staging
The neck is staged as set out elsewhere in this supple-
ment. It should be noted that the correct T stage for an
unknown primary is T0 and not TX.
Treatment
The aim of the treatment of the majority of patients
with a ‘true’ unknown primary tumour in the head
and neck should be curative with the least morbidity
to the upper aerodigestive tract possible. The treatment
of an occult mucosal primary is often assumed and
based on the well-studied natural history of mucosal
squamous cell cancers of the upper aerodigestive
tract. Most treatment regimens will therefore involve
combined modality treatment, but on occasions, radio-
therapy (RT), and even more rarely surgery, will be
used as single modality treatment.12 The rate of emer-
gence of the primary tumour is approximately 3 per
cent per year, which is equivalent to the development
of second carcinomas in the head and neck, lung and
oesophagus. Therefore the primary aim of treatment
is locoregional control. However, the rarity of
unknown primaries (approximately 1–2 per cent of
all squamous head and neck cancers) means there is a
dearth of literature to guide best practice. Many of the
management decisions are therefore controversial,
and based on individual centre case series.
Recommendations
• All patients presenting with confirmed
cervical lymph node metastatic SCC and no
apparent primary site should undergo:
• Positron emission tomography–computed
tomography whole-body scan (R)
• Panendoscopy and directed biopsies (R)
• Bilateral tonsillectomy (R)
• Tongue base mucosectomy can be offered if
facilities and expertise exist (G)
Surgery on its own may be sufficient treatment for N1
necks demonstrating no extracapsular spread, but in all
other scenarios, needs to be supplemented by adjuvant
(chemo) radiation (Table II).
For more advanced neck disease intensive combined
treatment is required. This could be either a combin-
ation of neck dissection and RT or initial (chemo)-
radiotherapy followed by planned neck dissection if a
complete response is not evident on imaging. Both of
these approaches appear to be equally effective. Of
emerging significance is the question of HPV 16 and
18 positivity and the effect it has on treatment recom-
mendations. Given the apparent good clinical response
to HPV-positive lymph nodes then the question arises
as to the advisability of surgical clearance of the neck
with or without adjuvant (chemo) radiotherapy or
whether primary RT should be considered as the only
treatment modality in this specific group.
Surgery
T0N1
T0N1 – no extracapsular spread. Patients presenting
with N1 disease and who are subsequently confirmed
following surgery as having pN1 disease without extra-
capsular spread may be treated with surgery alone pro-
vided the surgery has been comprehensive. This should
be in the form of a modified radical neck dissection
(MRND), including levels 1–5, and in the vast majority
preserving the ipsilateral sternomastoid muscle, intern-
al jugular vein and accessory nerve. This has been
shown to be as effective as RT and clearly avoids the
potential side effects of RT. There are no randomised
data to support MRND over selective neck dissection
(SND).13 However, in the absence of other adjunctive
therapies for the N1 neck, a MRND may be preferred
as its extent and subsequent radiological assessment
may avoid the need for radiation.
T0N1 – with extracapsular spread. When extracapsular
spread is found, however, then RT to at least the
involved nodal levels is necessary, although it is more
usual to irradiate the entire ipsilateral post-operative
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neck, and boost the involved levels. The addition of
chemotherapy to RT for occult primary head and neck
cancer has not yet been established. However, as post-
operative chemoradiation has been demonstrated to be
superior to post-operative radiation alone in the context
of pathologically confirmed extracapsular spread, in
patients with detectable upper aerodigestive tract
cancers, the addition of concomitant platinum-based
chemotherapy to radiation should be considered.14
There are no robust data to support the additional use
of total mucosal irradiation (TMI) with ipsilateral neck
radiation following neck dissection for T0pN1 disease.
There are also some reports that locoregional tumour
control is up to 40 per cent higher with surgery and
radiation therapy compared with radiation alone,
meaning radiation alone, even for N1 disease, must
remain an option only for those who are inoperable
on medical grounds or where it is considered appropri-
ate for those who are HPV positive.
T0N2a, T0N2b and T0N2c
For each of these stages comprehensive clearance of the
involved lymph node levels is usually required in the
form of MRND or SND with possible contralateral
SND or MRND. The rate of regional recurrence for
SND is similar to reported rates for MRND, when com-
bined with adjuvant radiation, such that SND may be
an appropriate surgical option for more advanced
neck disease in selected patients. Equally in less
advanced disease it has been reported that SND can
be used with similar efficacy to MRND. Radical RT
to one or both sides of the neck should be considered,
even for pN2a disease, as in one of the largest series of
occult primary head and neck cancer in 136 patients
from the MD Anderson Centre, combined surgery
and post-operative radiation was associated with
lower rates of locoregional relapse and higher
disease-free survival. This radiation may be given
with or without concomitant chemotherapy as
described above. While there remains no randomised
data to support the use of chemotherapy for pN2
disease from an occult head and neck primary, there
are two case series both demonstrating excellent pro-
gression-free survival (PFS) and overall survival (OS)
rates. The chemotherapy protocols used were heteroge-
neous, and included concomitant cisplatin, concomi-
tant 5-fluorouracil (5-FU) and hydroxyurea, as well
as paclitaxel.
In the absence of supportive data, radiation of poten-
tial index sites, depending on the lymph nodes levels
involved, remains controversial. It should remain an
area of active investigation, with the conventional man-
agement of patients with pN2 disease being as described
above.
T0N3
It may not be possible to have a curative aim in patients
with this staging. There is, however, a potential role for
surgery as palliation, in the form of a radical neck dissec-
tion with the aim of preventing or delaying, the onset
of fungation of the nodal metastasis. For curative intent
a radical neck dissection or Type I MRND with post-
operative chemoradiotherapy will usually be necessary.
Radiotherapy
Primary treatment. For N1 disease with extracapsular
spread, N2 and N3 disease, initial chemoradiation
with planned neck dissection only for those patients
not achieving a clinical or metabolic complete response
on post-treatment imaging is a valid management strat-
egy.12,15 The extent of the RT fields to be treated is
controversial. In the absence of high-level evidence,
the practice of radiation therapy in this setting includes
involved field only or bilateral neck and TMI. The latter
is practiced commonly in the UK.
Adjuvant treatment. There is a lack of consensus on the
RT target volumes that should be treated after neck dis-
section.16 Treatment of the ipsilateral hemi-neck alone
is of considerably lower toxicity and has been shown to
achieve local control rates in the cervical nodes of 90
per cent with contralateral relapse rates as low as 4.7
per cent, provided treatment strategies are determined
using PET–CT. However, total mucosal and bilateral
neck irradiation of the head and neck region is a
common practice with the aim of eradicating the
primary and the microscopic neck disease.
With the addition of cisplatin to primary RT for the
treatment of head and neck cancer, an absolute
survival benefit of 6.5 per cent is seen at five years.
Investigating concomitant chemoradiation in the post-
operative setting, the Radiation Therapy Oncology
Group (RTOG) demonstrated a 10 per cent improvement
in locoregional control rate, and a 22 per cent risk reduc-
tion of disease recurrence and death at two years, while
the European Organisation for Research and Treatment
TABLE II
TREATMENT RECOMMENDATIONS
Stage Surgery Radiotherapy Chemotherapy
T0N1 (no ECS) SND or MRND No unless for mucosal sites No
T0N1 (ECS) SND or MRND Yes – either involved lymph nodes or ipsilateral
neck and boost to involved lymph nodes
Should be considered
T0N2a, N2b, N2c SND or MRND±contralateral
SND or MRND
Yes – ipsilateral but bilateral should be considered Should be considered
T0N3 Radical or type I MRND Yes – ipsilateral but bilateral should be considered Should be considered
SND= selective neck dissection; MRND=modified radical neck dissection
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ofCancer (EORTC) group showed a 13per cent improve-
ment in locoregional control, 25 per cent risk reduction of
disease progression, and 30 per cent risk reduction of
death at five years.14,17 These findings were based on
the concomitant use of cisplatin 100 mg/m2 on days 1,
22 and43,whichmust therefore remain thegold standard.
Total mucosal irradiation. This remains a controversial
issue. In the largest series to date, no patient developed
a metachronous primary in the follow-up period, and so
would have experienced only toxicity rather than
benefit from TMI. Some groups have recommended
bilateral neck and TMI for occult primary head and
neck cancer patients, claiming improved local control,
but no OS benefit. There is no conclusive evidence to
support the routine use of TMI.
What is clear, however, is that with conventional RT
techniques, TMI is given at the price of significant
acute toxicity and chronic morbidity, mainly xerosto-
mia with its associated complications and effects on
quality of life. Intensity modulated radiation therapy
(IMRT) enables delivery of different doses during
TMI, thus potentially reducing treatment related tox-
icity. Four centres have reported their experience of
using IMRT to deliver TMI for unknown primaries,
with excellent two-year locoregional control (85–88
per cent) and OS (74–85 per cent). The MD
Anderson group, however, has most recently reported
the most mature data, with five-year actuarial locore-
gional control of 94 per cent and OS of 89 per cent.18
The TMI in all reports was well tolerated, and with sig-
nificantly reduced xerostomia and mucositis. Due to
the lack of randomised evidence, the post-operative
RT volume treated should therefore be at the discretion
of the treating clinician. If TMI is advocated the use of
IMRT is recommended.19,20
Radiation dosage schedules:
• Post-operative neck: 60 Gy in 30 fractions or
equivalent
• Post-operative neck with extracapsular spread:
64–66 Gy in 32–33 fractions or equivalent
• Gross macroscopic disease still present: 70 Gy in
30 fractions or equivalent
• Putative mucosal sites and the uninvolved neck:
50 Gy in 25 fractions or equivalent.
Chemotherapy
In the absence of randomised data to support chemo-
therapy, either before, during or after radiation for
occult primary head and neck cancer, the indications
for chemotherapy with post-operative or radical RT
should be as for treatment of patients with detectable
head and neck SCCs. The chemotherapy regimen
used is at the discretion of the treating clinician, but
will usually be platinum-based, single-agent cisplatin
or carboplatin or cetuximab in patients with suboptimal
renal function.
Recommendations
• Concomitant chemotherapy with radiation
should be considered in patients with an
unknown primary (R)
• Concomitant chemotherapy with radiation
should be offered to suitable patients in the
post-operative setting, where indicated (R)
• Neo-adjuvant chemotherapy can be used in
gross ‘unresectable’ disease (R)
Neo-adjuvant chemotherapy. While the meta-analysis
of chemotherapy in head and neck cancer (MACH-
NC) failed to demonstrate a significant benefit for
the use of induction chemotherapy,21 many of the his-
torical trials included pre-dated the use of taxanes.
Both the EORTC 24971 and TAX 323 studies and
the TAX 324 trial found that the addition of docetaxel
(T) to cisplatin (P) and 5-FU resulted in improved
PFS, OS and response rate and yet lower associated
toxicity. In the context of gross unresectable neck
disease, it therefore seems reasonable to consider the
use of such induction chemotherapy, particularly for
patients with excellent performance status, as a cyto-
reductive measure prior to definitive concomitant che-
moradiation, even for occult primary disease. The
caveat remains that the outcome of such case series
should be reported in the literature where possible,
for this rare group.
Concomitant chemotherapy. The addition of post-opera-
tive adjuvant chemotherapy concurrently with radiation
has transformed with the publication of two trials from
EORTC and RTOG. See section ‘Adjuvant treatment’
for detailed discussion.
Adjuvant chemotherapy. There are no convincing data
that chemotherapy given after radiation or surgery is
of benefit in terms of either disease-free or OS for
patients with detectable primaries. This approach
cannot therefore be recommended for patients with
occult primary head and neck cancer.
Recommendations
• Patients should be followed up at least two
months in the first two years and three to six
months in the subsequent years (G)
• Patients should be followed up to a minimum
of five years with a prolonged follow-up for
selected patients (G)
• Positron emission tomography–computed
tomography scan at three to four months after
treatment is a useful follow-up strategy for
patients treated by chemoradiation therapy (R)




Follow-up schedules should be in keeping with the
monitoring of all patients who have received treatment
for low-volume head and neck SCC with cervical
metastasis, as discussed elsewhere in these guidelines.
The highest risk period for relapse of squamous carcin-
oma following treatment occurs in the first two years. A
frequent follow-up programme of monitoring every 4
weeks up to 18 months is indicated for patients who
have received radical treatment. This should identify
the appearance of a primary, or any recurrence, in
turn allowing their prompt and optimal management.
As previously discussed, PET–CT is frequently a
standard part of the work up for patients presenting
with cervical metastasis from an occult primary. There
are data to suggest that it also plays a useful role in
follow-up. A negative PET–CT scan after treatment
with chemoradiotherapy is associated with a high nega-
tive predictive value (>95 per cent), and a negative scan
undertaken three to four months after completion of
therapy can therefore provide some reassurance for the
patient and clinician that there is no residual disease.
However, there are no data on the value of subsequent
imaging to monitor either subclinical locoregional recur-
rence or the development of a primary cancer, at a later
stage. The decision regarding subsequent imaging,
whether annually or otherwise, remains therefore at the
discretion of the treating clinician.
Key points
• All patients with a clinical unknown primary
should have comprehensive imaging, including
positron emission tomography–computed tomog-
raphy imaging, followed by panendoscopy and
bilateral tonsillectomy
• In the majority of cases, radical treatment should
include surgical clearance of the neck followed
by chemoradiotherapy
• Primary concurrent chemoradiation with planned
neck dissection or neck salvage based on response
is a valid alternative treatment strategy
• If total mucosal irradiation is to be considered,
then intensity modulated radiation therapy
should be used
• Follow-up should be similar to that employed in
patients who have received the treatment for an
identified tumour of the head and neck.
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